Zedira Presents Clinical Candidate for Celiac Disease Therapy

24-Sep-2009 - Germany

In course of the Chicago celiac disease Conference preclinical data has been presented supporting the selection of Zedira’s novel Transglutaminase blocker ZED-101 as clinical candidate for the treatment of celiac disease.

Blocking tissue transglutaminase is a promising therapeutic option in celiac disease. Zedira developed rationally designed peptidomimetic blockers bearing a michael acceptor pharmacophore. The safety profile and selectivity over other transglutaminase isoenzymes make ZED-101 an optimal candidate for subsequent clinical development.

Zedira considers either out-licensing ZED-101 to a pharmaceutical company or further conducting preclinical and clinical trials backed by investors.

Other news from the department research and development

More news from our other portals

All FT-IR spectrometer manufacturers at a glance